论文部分内容阅读
肝细胞性肝癌(hepatocellular carcinoma,HCC)是临床常见的恶性肿瘤之一,位居全球恶性肿瘤死因的第三位,其发生发展是多因素、多阶段、多基因突变的复杂病变过程。由于HCC早期诊断困难,术后易于复发转移,生存期短,除了传统的手术治疗、放疗和化疗外,靶向治疗、基因治疗也是目前肝癌研究的热点。Bcl-2与Bax(Bcl-2是Bcl-2家族成员中调控细胞凋亡最具代表性的基因,在多种肿瘤中都有表达,与
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in clinical practice. It ranks third in the cause of death from malignant tumors in the world. Its occurrence and development are complex and multi-factorial, multi-stage and multi-gene mutations. Because of the difficulty of early diagnosis of HCC, postoperative recurrence and metastasis, short survival, in addition to the traditional surgical treatment, radiotherapy and chemotherapy, targeted therapy, gene therapy is currently the focus of the study of liver cancer. Bcl-2 and Bax (Bcl-2 is the most representative gene regulating apoptosis in Bcl-2 family members and is expressed in a variety of tumors,